- 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?<p>Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline</p>BioPharma Dive · 1mo ago↗ source
- Oculis’ eye drops for diabetic macular edema flunk Phase 3 testOculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS…Endpoints · 1mo ago↗ source
- #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that goodCHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.…Endpoints